Chen Xuejun, Wang Shanshan, Wu Jie, Duan Shuwei, Wang Xiaolong, Hong Xiaoxuan, Han Xiaolu, Li Conghui, Kang Dongzhou, Wang Zengming, Zheng Aiping
Pharmaceutical Experiment Center, College of Pharmacy, Yanbian University, Yanji 133002, China.
State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Pharmaceutics. 2022 Nov 24;14(12):2589. doi: 10.3390/pharmaceutics14122589.
Three-dimensional (3D) printing is an additive manufacturing technique that creates objects under computer control. Owing to the rapid advancement of science and technology, 3D printing technology has been widely utilized in processing and manufacturing but rarely used in the pharmaceutical field. The first commercial form of Spritam immediate-release tablet was approved by FDA in 2015, which promoted the advancement of 3D printing technology in pharmaceutical development. Three-dimensional printing technology is able to meet individual treatment demands with customized size, shape, and release rate, which overcomes the difficulties of traditional pharmaceutical technology. This paper intends to discuss the critical process parameters of binder jet 3D printing technology, list its application in pharmaceutical manufacturing in recent years, summarize the still-open questions, and demonstrate its great potential in the pharmaceutical industry.
三维（3D）打印是一种增材制造技术，可在计算机控制下创建物体。由于科学技术的快速发展，3D打印技术已广泛应用于加工制造，但在制药领域却很少使用。速溶Spritam片剂的首个商业形式于2015年获得美国食品药品监督管理局（FDA）批准，这推动了3D打印技术在药物研发中的进步。三维打印技术能够通过定制的尺寸、形状和释放速率满足个性化治疗需求，克服了传统制药技术的难题。本文旨在探讨粘结剂喷射3D打印技术的关键工艺参数，列举其近年来在药物制造中的应用，总结尚待解决的问题，并展示其在制药行业的巨大潜力。
Zotero 插件
